PHGE
- BiomX Inc.
()
Overview
Company Summary
BiomX Inc. is a biotechnology company that specializes in the discovery and development of innovative therapies to address various diseases caused by dysbiosis - an imbalance in the natural microbial community within the body. Specifically, the company focuses on leveraging the potential of the human microbiome, which consists of trillions of microorganisms living within us, to develop novel treatments.
BiomX works on identifying and characterizing specific bacteria strains that play a role in human health and disease. By studying the interactions between these bacteria and the host, BiomX aims to understand the underlying mechanisms that lead to dysbiosis-associated conditions, such as inflammatory bowel disease (IBD), colorectal cancer, and even certain skin disorders.
Using their proprietary platform, called XMarker, BiomX identifies unique targets within the microbiome that can be modulated to restore a balanced microbial community. XMarker combines metagenomics, transcriptomics, and computational biology to identify genes and mechanisms related to microbial dysbiosis. This approach allows the company to develop microbial-based therapeutics, targeting specific strains or actions, to restore microbial balance and potentially improve patient outcomes.
BiomX also collaborates with academic institutions, hospitals, and industry partners to validate discoveries and advance their research further. Additionally, the company is actively involved in clinical studies to test the safety and efficacy of their microbiome-based therapies.
Overall, BiomX Inc. focuses on harnessing the potential of the human microbiome to develop innovative treatments for dysbiosis-related diseases and aims to make a significant impact in improving patients' lives through their biotechnology advancements.